IDEAYA Biosciences

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

by

Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancers Observed partial response by RECIST 1.1 (~40% tumor reduction) at first post-baseline scan in a pre-treated patient having a high priority MTAP-deletion solid tumor type Clinical strategy focused on IDE397 combinations, including with AMG … Read more

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

by

SOUTH SAN FRANCISCO, Calif., May 26, 2023 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 25, 2023, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of … Read more

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

by

IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid tumors Potential first-in-class synthetic lethality combination targets mechanistically complementary nodes of the MTAP methylation pathway – MAT2A and PRMT5 Compelling preclinical anti-tumor efficacy presented at AACR 2023 with durable CRs for IDE397 / AMG 193 combination, … Read more